Maher Masoud profile page

Maher Masoud was named president and chief executive officer of MaxCyte in January of 2024. He brings more than 25 years of experience in the biopharmaceutical industry, including 17 years as an attorney and general counsel, to his new role at MaxCyte. Masoud has most recently served as executive vice president, head of global business development, and chief counsel at MaxCyte. During his tenure, MaxCyte’s strategic platform license partnerships grew to include 29 partners (as of September 2024). Masoud started his biopharmaceutical career as a research associate with Glen Research, a Maravai company, before joining Human Genome Sciences as director and corporate counsel, overseeing legal activities for the company’s global clinical trials until its acquisition by GlaxoSmithKline. Prior to joining MaxCyte, Masoud oversaw the operations of six business subsidiaries at Wellstat, a life science holding company. During his tenure at Human Genome Sciences and Wellstat, Masoud supported the launch of three FDA-approved therapies, Benlysta®, Vistogard® and Xuriden®. Masoud earned his Juris Doctor degree from Michigan State University College of Law after completing his Bachelor of Science degree in cell and molecular biology genetics at the University of Maryland.